Status:

RECRUITING

NeuroPathways Intervention for Brain Tumor Patients

Lead Sponsor:

Massachusetts General Hospital

Conditions:

Malignant Brain Tumor

Glioma

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

This goal of this study is to test an information and support intervention for patients with malignant (or "high-grade") brain tumors. This study was developed to help patients cope after a brain tumo...

Detailed Description

This study will be a prospective pilot randomized controlled trial to examine the feasibility and acceptability of a novel, population-specific intervention designed to help patients with recently-dia...

Eligibility Criteria

Inclusion

  • Age ≥18
  • Massachusetts General Hospital Cancer Center patient
  • Within 6 weeks of diagnosis with a primary malignant brain tumor
  • Able to speak and read in English

Exclusion

  • Inability to provide informed consent as assessed by the study team (e.g., due to neurological impairment such as severe cognitive impairment/dementia or moderate-to-severe receptive aphasia)
  • Deemed inappropriate to approach by patient's oncologist or study PI

Key Trial Info

Start Date :

November 7 2023

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

April 10 2027

Estimated Enrollment :

50 Patients enrolled

Trial Details

Trial ID

NCT05976490

Start Date

November 7 2023

End Date

April 10 2027

Last Update

December 17 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Massachusetts General Hospital Cancer Center

Boston, Massachusetts, United States, 02114

NeuroPathways Intervention for Brain Tumor Patients | DecenTrialz